"Improved drug discovery platforms" is Daphnia Labs's model, and it's not just us, it includes lots of tech-enabled biotech startups (Recursion, BioAge, Verge Genomics, etc.) In Silicon Valley, these are success stories. In pharma as a whole, they're seen as speculative.
-
-
to actually commit to the platform-driven model all the way into the clinic, instead of pivoting away too early. And that will require some initiative and strategy.
Show this threadThanks. Twitter will use this to make your timeline better. UndoUndo
-
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.